ACAT2 as a novel therapeutic target to treat fatty liver disease-Reference-Cited by-同舟云学术

ACAT2 as a novel therapeutic target to treat fatty liver disease

Published:2022-02-10 Issue:2 Volume:292 Page:175-176
ISSN:0954-6820
Container-title:Journal of Internal Medicine
language:en
Short-container-title:J Intern Med

Author:

Romeo Stefano¹²³^ORCID

Affiliation:

1. Department of Molecular and Clinical Medicine Institute of Medicine Sahlgrenska Academy Wallenberg Laboratory University of Gothenburg Gothenburg Sweden

2. Department of Cardiology Sahlgrenska University Hospital Gothenburg Sweden

3. Clinical Nutrition Unit Department of Medical and Surgical Sciences University Magna Graecia Catanzaro Italy

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.13460

Reference11 articles.

1. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

2. Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease

3. MAFLD vs NAFLD: Let the contest begin!

4. LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover

5. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lentinan Ameliorates β-Hydroxybutyrate-Induced Lipid Metabolism Disorder in Bovine Hepatocytes by Upregulating the Expression of Acetyl-coenzyme A Acetyltransferase 2;Journal of Agricultural and Food Chemistry;2024-07-26

2. Cholesterol: A friend to viruses;International Reviews of Immunology;2024-02-19

3. NME4 mediates metabolic reprogramming and promotes nonalcoholic fatty liver disease progression;EMBO Reports;2023-12-14

4. Subclinical ketosis leads to lipid metabolism disorder by downregulating the expression of acetyl-coenzyme A acetyltransferase 2 in dairy cows;Journal of Dairy Science;2023-12